nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Skin exfoliation—Sorafenib—thyroid cancer	0.0106	0.0107	CcSEcCtD
Metolazone—Neuropathy—Sorafenib—thyroid cancer	0.0104	0.0105	CcSEcCtD
Metolazone—Pancreatitis—Vandetanib—thyroid cancer	0.0101	0.0102	CcSEcCtD
Metolazone—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00944	0.00953	CcSEcCtD
Metolazone—Hyperglycaemia—Vandetanib—thyroid cancer	0.00933	0.00942	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00914	0.00923	CcSEcCtD
Metolazone—Epistaxis—Vandetanib—thyroid cancer	0.0087	0.00878	CcSEcCtD
Metolazone—Hyponatraemia—Sorafenib—thyroid cancer	0.0081	0.00818	CcSEcCtD
Metolazone—Erythema multiforme—Vandetanib—thyroid cancer	0.00783	0.0079	CcSEcCtD
Metolazone—Venous thrombosis—Epirubicin—thyroid cancer	0.00761	0.00769	CcSEcCtD
Metolazone—Dry skin—Sorafenib—thyroid cancer	0.0074	0.00747	CcSEcCtD
Metolazone—Hypokalaemia—Sorafenib—thyroid cancer	0.00735	0.00742	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00727	0.00734	CcSEcCtD
Metolazone—Hypophosphataemia—Epirubicin—thyroid cancer	0.00707	0.00714	CcSEcCtD
Metolazone—Dysgeusia—Vandetanib—thyroid cancer	0.00706	0.00713	CcSEcCtD
Metolazone—Venous thrombosis—Doxorubicin—thyroid cancer	0.00704	0.00711	CcSEcCtD
Metolazone—Muscle spasms—Vandetanib—thyroid cancer	0.00693	0.007	CcSEcCtD
Metolazone—Pancreatitis—Sorafenib—thyroid cancer	0.00684	0.00691	CcSEcCtD
Metolazone—Vision blurred—Vandetanib—thyroid cancer	0.00679	0.00686	CcSEcCtD
Metolazone—Abdominal discomfort—Sorafenib—thyroid cancer	0.00669	0.00675	CcSEcCtD
Metolazone—Hypophosphataemia—Doxorubicin—thyroid cancer	0.00654	0.00661	CcSEcCtD
Metolazone—Hypomagnesaemia—Epirubicin—thyroid cancer	0.00647	0.00653	CcSEcCtD
Metolazone—Erectile dysfunction—Sorafenib—thyroid cancer	0.00643	0.00649	CcSEcCtD
Metolazone—Loss of consciousness—Vandetanib—thyroid cancer	0.00633	0.00639	CcSEcCtD
Metolazone—Cough—Vandetanib—thyroid cancer	0.00629	0.00635	CcSEcCtD
Metolazone—Hypertension—Vandetanib—thyroid cancer	0.00622	0.00628	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00617	0.00623	CcSEcCtD
Metolazone—Chest pain—Vandetanib—thyroid cancer	0.00613	0.00619	CcSEcCtD
Metolazone—Arthralgia—Vandetanib—thyroid cancer	0.00613	0.00619	CcSEcCtD
Metolazone—Anxiety—Vandetanib—thyroid cancer	0.00611	0.00617	CcSEcCtD
Metolazone—Neuropathy peripheral—Sorafenib—thyroid cancer	0.0061	0.00616	CcSEcCtD
Metolazone—Dry mouth—Vandetanib—thyroid cancer	0.006	0.00606	CcSEcCtD
Metolazone—Hypomagnesaemia—Doxorubicin—thyroid cancer	0.00599	0.00604	CcSEcCtD
Metolazone—Hypercalcaemia—Epirubicin—thyroid cancer	0.00592	0.00597	CcSEcCtD
Metolazone—Epistaxis—Sorafenib—thyroid cancer	0.00587	0.00592	CcSEcCtD
Metolazone—Thrombocytopenia—Vandetanib—thyroid cancer	0.00576	0.00581	CcSEcCtD
Metolazone—Hypercalcaemia—Doxorubicin—thyroid cancer	0.00547	0.00553	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00536	0.00541	CcSEcCtD
Metolazone—Insomnia—Vandetanib—thyroid cancer	0.00532	0.00537	CcSEcCtD
Metolazone—Paraesthesia—Vandetanib—thyroid cancer	0.00528	0.00533	CcSEcCtD
Metolazone—Erythema multiforme—Sorafenib—thyroid cancer	0.00528	0.00533	CcSEcCtD
Metolazone—Tinnitus—Sorafenib—thyroid cancer	0.00521	0.00526	CcSEcCtD
Metolazone—Dyspepsia—Vandetanib—thyroid cancer	0.00518	0.00523	CcSEcCtD
Metolazone—Decreased appetite—Vandetanib—thyroid cancer	0.00511	0.00516	CcSEcCtD
Metolazone—Glycosuria—Epirubicin—thyroid cancer	0.00507	0.00512	CcSEcCtD
Metolazone—Fatigue—Vandetanib—thyroid cancer	0.00507	0.00512	CcSEcCtD
Metolazone—Pain—Vandetanib—thyroid cancer	0.00503	0.00508	CcSEcCtD
Metolazone—Constipation—Vandetanib—thyroid cancer	0.00503	0.00508	CcSEcCtD
Metolazone—Petechiae—Epirubicin—thyroid cancer	0.005	0.00504	CcSEcCtD
Metolazone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00481	0.00486	CcSEcCtD
Metolazone—Dysgeusia—Sorafenib—thyroid cancer	0.00476	0.00481	CcSEcCtD
Metolazone—Glycosuria—Doxorubicin—thyroid cancer	0.00469	0.00474	CcSEcCtD
Metolazone—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00468	0.00472	CcSEcCtD
Metolazone—Muscle spasms—Sorafenib—thyroid cancer	0.00467	0.00472	CcSEcCtD
Metolazone—Abdominal pain—Vandetanib—thyroid cancer	0.00465	0.00469	CcSEcCtD
Metolazone—Petechiae—Doxorubicin—thyroid cancer	0.00462	0.00467	CcSEcCtD
Metolazone—Anaemia—Sorafenib—thyroid cancer	0.00449	0.00454	CcSEcCtD
Metolazone—Hyperuricaemia—Epirubicin—thyroid cancer	0.00443	0.00447	CcSEcCtD
Metolazone—Nocturia—Epirubicin—thyroid cancer	0.00443	0.00447	CcSEcCtD
Metolazone—Syncope—Sorafenib—thyroid cancer	0.00436	0.0044	CcSEcCtD
Metolazone—Leukopenia—Sorafenib—thyroid cancer	0.00435	0.00439	CcSEcCtD
Metolazone—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00433	0.00437	CcSEcCtD
Metolazone—Loss of consciousness—Sorafenib—thyroid cancer	0.00427	0.00431	CcSEcCtD
Metolazone—Cough—Sorafenib—thyroid cancer	0.00424	0.00428	CcSEcCtD
Metolazone—Asthenia—Vandetanib—thyroid cancer	0.00422	0.00426	CcSEcCtD
Metolazone—Hypertension—Sorafenib—thyroid cancer	0.0042	0.00424	CcSEcCtD
Metolazone—Blood uric acid increased—Epirubicin—thyroid cancer	0.00418	0.00423	CcSEcCtD
Metolazone—Pruritus—Vandetanib—thyroid cancer	0.00416	0.0042	CcSEcCtD
Metolazone—Arthralgia—Sorafenib—thyroid cancer	0.00414	0.00418	CcSEcCtD
Metolazone—Nocturia—Doxorubicin—thyroid cancer	0.0041	0.00414	CcSEcCtD
Metolazone—Hyperuricaemia—Doxorubicin—thyroid cancer	0.0041	0.00414	CcSEcCtD
Metolazone—Dry mouth—Sorafenib—thyroid cancer	0.00405	0.00409	CcSEcCtD
Metolazone—Diarrhoea—Vandetanib—thyroid cancer	0.00402	0.00406	CcSEcCtD
Metolazone—Skin exfoliation—Epirubicin—thyroid cancer	0.00392	0.00396	CcSEcCtD
Metolazone—Shock—Sorafenib—thyroid cancer	0.0039	0.00394	CcSEcCtD
Metolazone—Dizziness—Vandetanib—thyroid cancer	0.00389	0.00393	CcSEcCtD
Metolazone—Thrombocytopenia—Sorafenib—thyroid cancer	0.00388	0.00392	CcSEcCtD
Metolazone—Blood urea increased—Epirubicin—thyroid cancer	0.00388	0.00392	CcSEcCtD
Metolazone—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00387	0.00391	CcSEcCtD
Metolazone—Neuropathy—Epirubicin—thyroid cancer	0.00386	0.0039	CcSEcCtD
Metolazone—Anorexia—Sorafenib—thyroid cancer	0.00378	0.00382	CcSEcCtD
Metolazone—Vomiting—Vandetanib—thyroid cancer	0.00374	0.00378	CcSEcCtD
Metolazone—Rash—Vandetanib—thyroid cancer	0.00371	0.00374	CcSEcCtD
Metolazone—Dermatitis—Vandetanib—thyroid cancer	0.0037	0.00374	CcSEcCtD
Metolazone—Headache—Vandetanib—thyroid cancer	0.00368	0.00372	CcSEcCtD
Metolazone—Skin exfoliation—Doxorubicin—thyroid cancer	0.00363	0.00367	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00361	0.00365	CcSEcCtD
Metolazone—Blood urea increased—Doxorubicin—thyroid cancer	0.00359	0.00362	CcSEcCtD
Metolazone—Neuropathy—Doxorubicin—thyroid cancer	0.00357	0.0036	CcSEcCtD
Metolazone—Nausea—Vandetanib—thyroid cancer	0.00349	0.00353	CcSEcCtD
Metolazone—Dyspepsia—Sorafenib—thyroid cancer	0.00349	0.00353	CcSEcCtD
Metolazone—Decreased appetite—Sorafenib—thyroid cancer	0.00345	0.00348	CcSEcCtD
Metolazone—Fatigue—Sorafenib—thyroid cancer	0.00342	0.00345	CcSEcCtD
Metolazone—Photosensitivity—Epirubicin—thyroid cancer	0.0034	0.00343	CcSEcCtD
Metolazone—Constipation—Sorafenib—thyroid cancer	0.00339	0.00343	CcSEcCtD
Metolazone—Pain—Sorafenib—thyroid cancer	0.00339	0.00343	CcSEcCtD
Metolazone—Vascular purpura—Epirubicin—thyroid cancer	0.00333	0.00337	CcSEcCtD
Metolazone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00324	0.00328	CcSEcCtD
Metolazone—Urticaria—Sorafenib—thyroid cancer	0.00315	0.00318	CcSEcCtD
Metolazone—Photosensitivity—Doxorubicin—thyroid cancer	0.00314	0.00317	CcSEcCtD
Metolazone—Abdominal pain—Sorafenib—thyroid cancer	0.00314	0.00317	CcSEcCtD
Metolazone—Purpura—Epirubicin—thyroid cancer	0.0031	0.00313	CcSEcCtD
Metolazone—Vascular purpura—Doxorubicin—thyroid cancer	0.00309	0.00312	CcSEcCtD
Metolazone—Lethargy—Epirubicin—thyroid cancer	0.00304	0.00307	CcSEcCtD
Metolazone—Hyponatraemia—Epirubicin—thyroid cancer	0.003	0.00302	CcSEcCtD
Metolazone—Hypersensitivity—Sorafenib—thyroid cancer	0.00292	0.00295	CcSEcCtD
Metolazone—Purpura—Doxorubicin—thyroid cancer	0.00286	0.00289	CcSEcCtD
Metolazone—Asthenia—Sorafenib—thyroid cancer	0.00285	0.00287	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—thyroid cancer	0.00282	0.00284	CcSEcCtD
Metolazone—Pruritus—Sorafenib—thyroid cancer	0.00281	0.00283	CcSEcCtD
Metolazone—Hyponatraemia—Doxorubicin—thyroid cancer	0.00277	0.0028	CcSEcCtD
Metolazone—Dry skin—Epirubicin—thyroid cancer	0.00273	0.00276	CcSEcCtD
Metolazone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00272	0.00275	CcSEcCtD
Metolazone—Hypokalaemia—Epirubicin—thyroid cancer	0.00271	0.00274	CcSEcCtD
Metolazone—Diarrhoea—Sorafenib—thyroid cancer	0.00271	0.00274	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00269	0.00271	CcSEcCtD
Metolazone—Dizziness—Sorafenib—thyroid cancer	0.00262	0.00265	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—thyroid cancer	0.0026	0.00262	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—thyroid cancer	0.00253	0.00255	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—thyroid cancer	0.00253	0.00255	CcSEcCtD
Metolazone—Vomiting—Sorafenib—thyroid cancer	0.00252	0.00255	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00252	0.00255	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—thyroid cancer	0.00251	0.00254	CcSEcCtD
Metolazone—Rash—Sorafenib—thyroid cancer	0.0025	0.00253	CcSEcCtD
Metolazone—Dermatitis—Sorafenib—thyroid cancer	0.0025	0.00252	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00249	0.00251	CcSEcCtD
Metolazone—Headache—Sorafenib—thyroid cancer	0.00249	0.00251	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—thyroid cancer	0.0024	0.00242	CcSEcCtD
Metolazone—Nausea—Sorafenib—thyroid cancer	0.00236	0.00238	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00235	0.00238	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—thyroid cancer	0.00234	0.00236	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—thyroid cancer	0.00233	0.00235	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—thyroid cancer	0.0023	0.00232	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00228	0.0023	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00225	0.00228	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00218	0.0022	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—thyroid cancer	0.00217	0.00219	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00215	0.00217	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—thyroid cancer	0.00215	0.00217	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—thyroid cancer	0.00213	0.00215	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00211	0.00213	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00209	0.00211	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—thyroid cancer	0.00206	0.00208	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—thyroid cancer	0.00201	0.00203	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—thyroid cancer	0.00198	0.002	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—thyroid cancer	0.00195	0.00197	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—thyroid cancer	0.00192	0.00194	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—thyroid cancer	0.00191	0.00193	CcSEcCtD
Metolazone—Chills—Epirubicin—thyroid cancer	0.00185	0.00187	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—thyroid cancer	0.00181	0.00182	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—thyroid cancer	0.00178	0.0018	CcSEcCtD
Metolazone—Flatulence—Epirubicin—thyroid cancer	0.00177	0.00179	CcSEcCtD
Metolazone—Tension—Epirubicin—thyroid cancer	0.00176	0.00178	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—thyroid cancer	0.00176	0.00178	CcSEcCtD
Metolazone—Nervousness—Epirubicin—thyroid cancer	0.00174	0.00176	CcSEcCtD
Metolazone—Back pain—Epirubicin—thyroid cancer	0.00174	0.00175	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—thyroid cancer	0.00173	0.00174	CcSEcCtD
Metolazone—Chills—Doxorubicin—thyroid cancer	0.00171	0.00173	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—thyroid cancer	0.00169	0.00171	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—thyroid cancer	0.00167	0.00168	CcSEcCtD
Metolazone—Anaemia—Epirubicin—thyroid cancer	0.00166	0.00168	CcSEcCtD
Metolazone—Agitation—Epirubicin—thyroid cancer	0.00165	0.00167	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—thyroid cancer	0.00164	0.00165	CcSEcCtD
Metolazone—Tension—Doxorubicin—thyroid cancer	0.00163	0.00165	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—thyroid cancer	0.00163	0.00164	CcSEcCtD
Metolazone—Malaise—Epirubicin—thyroid cancer	0.00162	0.00164	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—thyroid cancer	0.00161	0.00163	CcSEcCtD
Metolazone—Vertigo—Epirubicin—thyroid cancer	0.00161	0.00163	CcSEcCtD
Metolazone—Syncope—Epirubicin—thyroid cancer	0.00161	0.00163	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—thyroid cancer	0.00161	0.00162	CcSEcCtD
Metolazone—Back pain—Doxorubicin—thyroid cancer	0.00161	0.00162	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—thyroid cancer	0.0016	0.00161	CcSEcCtD
Metolazone—Palpitations—Epirubicin—thyroid cancer	0.00159	0.0016	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—thyroid cancer	0.00158	0.00159	CcSEcCtD
Metolazone—Cough—Epirubicin—thyroid cancer	0.00157	0.00158	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—thyroid cancer	0.00157	0.00158	CcSEcCtD
Metolazone—Hypertension—Epirubicin—thyroid cancer	0.00155	0.00157	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00154	0.00156	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—thyroid cancer	0.00154	0.00155	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—thyroid cancer	0.00153	0.00154	CcSEcCtD
Metolazone—Chest pain—Epirubicin—thyroid cancer	0.00153	0.00154	CcSEcCtD
Metolazone—Agitation—Doxorubicin—thyroid cancer	0.00153	0.00154	CcSEcCtD
Metolazone—Anxiety—Epirubicin—thyroid cancer	0.00152	0.00154	CcSEcCtD
Metolazone—Discomfort—Epirubicin—thyroid cancer	0.00151	0.00153	CcSEcCtD
Metolazone—Malaise—Doxorubicin—thyroid cancer	0.0015	0.00151	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—thyroid cancer	0.0015	0.00151	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—thyroid cancer	0.00149	0.00151	CcSEcCtD
Metolazone—Syncope—Doxorubicin—thyroid cancer	0.00149	0.00151	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—thyroid cancer	0.00149	0.0015	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EPO—thyroid cancer	0.00149	0.155	CbGpPWpGaD
Metolazone—Palpitations—Doxorubicin—thyroid cancer	0.00147	0.00148	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—thyroid cancer	0.00146	0.00148	CcSEcCtD
Metolazone—Cough—Doxorubicin—thyroid cancer	0.00145	0.00146	CcSEcCtD
Metolazone—Shock—Epirubicin—thyroid cancer	0.00144	0.00146	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—thyroid cancer	0.00144	0.00145	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—thyroid cancer	0.00144	0.00145	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—thyroid cancer	0.00142	0.00143	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—thyroid cancer	0.00142	0.00143	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—thyroid cancer	0.00141	0.00142	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—thyroid cancer	0.0014	0.00141	CcSEcCtD
Metolazone—Anorexia—Epirubicin—thyroid cancer	0.0014	0.00141	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—thyroid cancer	0.00138	0.0014	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00134	0.00135	CcSEcCtD
Metolazone—Shock—Doxorubicin—thyroid cancer	0.00133	0.00135	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Metolazone—Insomnia—Epirubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—thyroid cancer	0.00132	0.00133	CcSEcCtD
Metolazone—Somnolence—Epirubicin—thyroid cancer	0.0013	0.00132	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—thyroid cancer	0.00129	0.00131	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—thyroid cancer	0.00129	0.0013	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—thyroid cancer	0.00127	0.00129	CcSEcCtD
Metolazone—Fatigue—Epirubicin—thyroid cancer	0.00126	0.00128	CcSEcCtD
Metolazone—Constipation—Epirubicin—thyroid cancer	0.00125	0.00127	CcSEcCtD
Metolazone—Pain—Epirubicin—thyroid cancer	0.00125	0.00127	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00124	0.00125	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—thyroid cancer	0.00123	0.00124	CcSEcCtD
Metolazone—Paraesthesia—Doxorubicin—thyroid cancer	0.00122	0.00123	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—thyroid cancer	0.00121	0.00122	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—thyroid cancer	0.00121	0.00122	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.0012	0.00121	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—thyroid cancer	0.00119	0.00121	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—thyroid cancer	0.00118	0.00119	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—thyroid cancer	0.00117	0.00118	CcSEcCtD
Metolazone—Urticaria—Epirubicin—thyroid cancer	0.00116	0.00118	CcSEcCtD
Metolazone—Pain—Doxorubicin—thyroid cancer	0.00116	0.00117	CcSEcCtD
Metolazone—Constipation—Doxorubicin—thyroid cancer	0.00116	0.00117	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—thyroid cancer	0.00116	0.00117	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—thyroid cancer	0.00112	0.00113	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00111	0.00112	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—thyroid cancer	0.00108	0.00109	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—thyroid cancer	0.00108	0.00109	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—thyroid cancer	0.00107	0.00108	CcSEcCtD
Metolazone—Asthenia—Epirubicin—thyroid cancer	0.00105	0.00106	CcSEcCtD
Metolazone—Pruritus—Epirubicin—thyroid cancer	0.00104	0.00105	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—thyroid cancer	0.001	0.00101	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000999	0.00101	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—thyroid cancer	0.000973	0.000983	CcSEcCtD
Metolazone—Dizziness—Epirubicin—thyroid cancer	0.00097	0.000979	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—thyroid cancer	0.00096	0.000969	CcSEcCtD
Metolazone—Vomiting—Epirubicin—thyroid cancer	0.000932	0.000941	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—thyroid cancer	0.000928	0.000937	CcSEcCtD
Metolazone—Rash—Epirubicin—thyroid cancer	0.000924	0.000933	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—thyroid cancer	0.000924	0.000933	CcSEcCtD
Metolazone—Headache—Epirubicin—thyroid cancer	0.000919	0.000927	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—thyroid cancer	0.000897	0.000906	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—thyroid cancer	0.000885	0.0922	CbGpPWpGaD
Metolazone—Nausea—Epirubicin—thyroid cancer	0.000871	0.000879	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—thyroid cancer	0.000863	0.000871	CcSEcCtD
Metolazone—Rash—Doxorubicin—thyroid cancer	0.000855	0.000864	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—thyroid cancer	0.000855	0.000863	CcSEcCtD
Metolazone—Headache—Doxorubicin—thyroid cancer	0.00085	0.000858	CcSEcCtD
Metolazone—Nausea—Doxorubicin—thyroid cancer	0.000806	0.000814	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—EPO—thyroid cancer	0.000657	0.0684	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—HIF1A—thyroid cancer	0.000391	0.0407	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000385	0.0401	CbGpPWpGaD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.000309	0.0322	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000302	0.0315	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000188	0.0196	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000184	0.0192	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000184	0.0192	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.00018	0.0187	CbGpPWpGaD
Metolazone—CA5A—Metabolism—MINPP1—thyroid cancer	0.000148	0.0154	CbGpPWpGaD
Metolazone—CA7—Metabolism—MINPP1—thyroid cancer	0.000138	0.0144	CbGpPWpGaD
Metolazone—CA5B—Metabolism—MINPP1—thyroid cancer	0.000138	0.0144	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000138	0.0144	CbGpPWpGaD
Metolazone—CA12—Metabolism—MINPP1—thyroid cancer	0.000128	0.0134	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NDUFA13—thyroid cancer	0.000126	0.0131	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CHST14—thyroid cancer	0.000119	0.0123	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NDUFA13—thyroid cancer	0.000118	0.0123	CbGpPWpGaD
Metolazone—CA7—Metabolism—NDUFA13—thyroid cancer	0.000118	0.0123	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CHST14—thyroid cancer	0.000111	0.0115	CbGpPWpGaD
Metolazone—CA7—Metabolism—CHST14—thyroid cancer	0.000111	0.0115	CbGpPWpGaD
Metolazone—CA12—Metabolism—NDUFA13—thyroid cancer	0.000109	0.0114	CbGpPWpGaD
Metolazone—CA12—Metabolism—CHST14—thyroid cancer	0.000103	0.0107	CbGpPWpGaD
Metolazone—CA4—Metabolism—MINPP1—thyroid cancer	0.000102	0.0107	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—EPO—thyroid cancer	9.96e-05	0.0104	CbGpPWpGaD
Metolazone—CA5A—Metabolism—HPGD—thyroid cancer	9.56e-05	0.00995	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—TPR—thyroid cancer	9.37e-05	0.00976	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—CP—thyroid cancer	9.37e-05	0.00976	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.22e-05	0.0096	CbGpPWpGaD
Metolazone—CA7—Metabolism—HPGD—thyroid cancer	8.92e-05	0.00929	CbGpPWpGaD
Metolazone—CA5B—Metabolism—HPGD—thyroid cancer	8.92e-05	0.00929	CbGpPWpGaD
Metolazone—CA4—Metabolism—NDUFA13—thyroid cancer	8.7e-05	0.00906	CbGpPWpGaD
Metolazone—CA9—Metabolism—MINPP1—thyroid cancer	8.27e-05	0.00861	CbGpPWpGaD
Metolazone—CA12—Metabolism—HPGD—thyroid cancer	8.27e-05	0.00861	CbGpPWpGaD
Metolazone—CA4—Metabolism—CHST14—thyroid cancer	8.18e-05	0.00851	CbGpPWpGaD
Metolazone—CA9—Metabolism—NDUFA13—thyroid cancer	7.03e-05	0.00732	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.01e-05	0.0073	CbGpPWpGaD
Metolazone—CA9—Metabolism—CHST14—thyroid cancer	6.61e-05	0.00688	CbGpPWpGaD
Metolazone—CA4—Metabolism—HPGD—thyroid cancer	6.59e-05	0.00686	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	6.04e-05	0.00629	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—HIF1A—thyroid cancer	5.93e-05	0.00617	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.89e-05	0.00614	CbGpPWpGaD
Metolazone—CA5A—Metabolism—TPR—thyroid cancer	5.49e-05	0.00572	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PRKAR1A—thyroid cancer	5.4e-05	0.00562	CbGpPWpGaD
Metolazone—CA9—Metabolism—HPGD—thyroid cancer	5.33e-05	0.00555	CbGpPWpGaD
Metolazone—CA7—Metabolism—TPR—thyroid cancer	5.12e-05	0.00534	CbGpPWpGaD
Metolazone—CA5B—Metabolism—TPR—thyroid cancer	5.12e-05	0.00534	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PRKAR1A—thyroid cancer	5.04e-05	0.00525	CbGpPWpGaD
Metolazone—CA7—Metabolism—PRKAR1A—thyroid cancer	5.04e-05	0.00525	CbGpPWpGaD
Metolazone—CA12—Metabolism—TPR—thyroid cancer	4.75e-05	0.00494	CbGpPWpGaD
Metolazone—CA12—Metabolism—PRKAR1A—thyroid cancer	4.67e-05	0.00486	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SLC5A5—thyroid cancer	4.11e-05	0.00428	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC5A5—thyroid cancer	3.84e-05	0.00399	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC5A5—thyroid cancer	3.84e-05	0.00399	CbGpPWpGaD
Metolazone—CA4—Metabolism—TPR—thyroid cancer	3.79e-05	0.00394	CbGpPWpGaD
Metolazone—CA4—Metabolism—PRKAR1A—thyroid cancer	3.72e-05	0.00388	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC5A5—thyroid cancer	3.55e-05	0.0037	CbGpPWpGaD
Metolazone—CA5A—Metabolism—RXRA—thyroid cancer	3.45e-05	0.00359	CbGpPWpGaD
Metolazone—CA7—Metabolism—RXRA—thyroid cancer	3.22e-05	0.00336	CbGpPWpGaD
Metolazone—CA5B—Metabolism—RXRA—thyroid cancer	3.22e-05	0.00336	CbGpPWpGaD
Metolazone—CA9—Metabolism—TPR—thyroid cancer	3.06e-05	0.00319	CbGpPWpGaD
Metolazone—CA9—Metabolism—PRKAR1A—thyroid cancer	3.01e-05	0.00313	CbGpPWpGaD
Metolazone—CA12—Metabolism—RXRA—thyroid cancer	2.99e-05	0.00311	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC5A5—thyroid cancer	2.83e-05	0.00295	CbGpPWpGaD
Metolazone—CA4—Metabolism—RXRA—thyroid cancer	2.38e-05	0.00248	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—thyroid cancer	2.36e-05	0.00246	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC5A5—thyroid cancer	2.29e-05	0.00238	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PPARG—thyroid cancer	2.18e-05	0.00227	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PPARG—thyroid cancer	2.03e-05	0.00212	CbGpPWpGaD
Metolazone—CA7—Metabolism—PPARG—thyroid cancer	2.03e-05	0.00212	CbGpPWpGaD
Metolazone—CA9—Metabolism—RXRA—thyroid cancer	1.92e-05	0.002	CbGpPWpGaD
Metolazone—CA12—Metabolism—PPARG—thyroid cancer	1.89e-05	0.00196	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS2—thyroid cancer	1.71e-05	0.00179	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS2—thyroid cancer	1.6e-05	0.00167	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS2—thyroid cancer	1.6e-05	0.00167	CbGpPWpGaD
Metolazone—CA4—Metabolism—PPARG—thyroid cancer	1.5e-05	0.00157	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTEN—thyroid cancer	1.5e-05	0.00156	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS2—thyroid cancer	1.48e-05	0.00154	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTEN—thyroid cancer	1.4e-05	0.00145	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTEN—thyroid cancer	1.4e-05	0.00145	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTEN—thyroid cancer	1.29e-05	0.00135	CbGpPWpGaD
Metolazone—CA9—Metabolism—PPARG—thyroid cancer	1.21e-05	0.00126	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS2—thyroid cancer	1.18e-05	0.00123	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTEN—thyroid cancer	1.03e-05	0.00107	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS2—thyroid cancer	9.56e-06	0.000995	CbGpPWpGaD
Metolazone—CA5A—Metabolism—AKT1—thyroid cancer	8.62e-06	0.000897	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTEN—thyroid cancer	8.33e-06	0.000868	CbGpPWpGaD
Metolazone—CA7—Metabolism—AKT1—thyroid cancer	8.05e-06	0.000838	CbGpPWpGaD
Metolazone—CA5B—Metabolism—AKT1—thyroid cancer	8.05e-06	0.000838	CbGpPWpGaD
Metolazone—CA12—Metabolism—AKT1—thyroid cancer	7.45e-06	0.000776	CbGpPWpGaD
Metolazone—CA4—Metabolism—AKT1—thyroid cancer	5.94e-06	0.000619	CbGpPWpGaD
Metolazone—CA9—Metabolism—AKT1—thyroid cancer	4.8e-06	0.0005	CbGpPWpGaD
